ArticleFrontiers in pharmacology2023

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy.

Wing Lam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.